BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Semaglutide

Risk of Thyroid C-Cell Tumors

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY & RYBELSUS causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined¬†[see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
  • WEGOVY & RYBELSUS is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)¬†[see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of RYBELSUS and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY & RYBELSUS¬†[see Contraindications (4) and Warnings and Precautions (5.1)]


Patient Counseling Information

Medication Guides

Patient Medication Guide - OZEMPIC

Patient Medication Guide - RYBELSUS

Patient Medication Guide - WEGOVY

Package Inserts

Semaglutide

Updated July 2021